In new study results, researchers from the University of Alabama at Birmingham found that administering the preventive epilepsy treatment vigabatrin prior to seizure onset did not improve ...

Background and aims: In term neonates with seizures, it is important to distinguish between hypoxic-ischaemic encephalopathy (HIE) and focal cerebral lesions as soon as possible to aid clinical ...

Please provide your email address to receive an email when new articles are posted on . Cannabidiol treatment was associated with median reduction of 67% to 99% in focal aware seizures. All ...

Patients with focal nonmotor seizures experience a "disproportionate delay to diagnosis" compared with those with focal motor seizures, especially among teens, new research suggests. Retrospective ...

“It’s all about the brain,” said Jennifer DeWolfe, D.O., professor in the UAB Department of Neurology. “Seizure manifestations are stereotyped, so the same symptoms occur with each seizure that ...

About 60-70% of focal epilepsy patients achieve seizure control with first-line antiseizure medications (ASMs). Lamotrigine and levetiracetam demonstrate high efficacy and tolerability for seizure ...

Ludwig-Maximilians-Universität München-led researchers have induced a greater than 60% reduction in seizure frequency in a preterm infant with early-onset SCN2A developmental and epileptic ...

Longitudinal data suggested that treatment-resistant focal epilepsy may improve over time. Nearly 70% had reduced seizure frequency and some patients achieved seizure freedom. Improvement was not ...

You can expect most epilepsy cases to improve with antiseizure drugs. Surgery is an option if medications do not work for your epilepsy. You may eat a ketogenic diet to help with treatment-resistant ...

Please provide your email address to receive an email when new articles are posted on . A total of 37% of study participants were seizure-free for at least 6 months. The researchers noted the positive ...

A new drug candidate has shown impressive results in a mid-stage clinical trial for drug-resistant epilepsy, raising hopes for patients who continue to suffer seizures despite being on multiple ...